Results 51 to 60 of about 21,372 (208)

Regulatory harmonization: Evolution, globalization and future directions

British Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm, Elaine Y. L. Blair, Christine Y. Lu   +2 more
wiley   +1 more source

Model‐Informed Dosing of Venetoclax in Healthy Subjects: An Exposure−Response Analysis

Clinical and Translational Science, 2019
Venetoclax is an approved drug for the treatment of some hematological malignancies. Venetoclax can cause reduction in B‐lymphocyte counts as an on‐target effect.
Nimita Dave, Sathej Gopalakrishnan, Sven Mensing, Ahmed Hamed Salem   +3 more
doaj   +1 more source

High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells [PDF]

, 2021
Neuroblastoma tumors frequently overexpress the anti-apoptotic protein B-cell lymphoma/leukemia 2 (BCL-2). We previously showed that treating BCL-2-dependent neuroblastoma cells with the BCL-2 inhibitor venetoclax results in apoptosis, but unfortunately ...
Alles, Lindy K, Pharmaceutics, Alles, Lindy K., Vernooij, Lindy, Stam, Ronald W., Koster, Jan, Bate-Eya, Laurel T., Dolman, M Emmy M, Schubert, Nil A, Kerstjens, Mark, Molenaar, Jan J., Dolman, M. M. Emmy, Koopmans, Bianca, Jonus, Hunter C., Egan, David A., Schild, Linda, Jonus, Hunter C, Lelieveld, Daphne, Molenaar, Jan J, Dolman, M. M.Emmy, Lee, Jasmine Y., Schubert, Nil A., Egan, David A, Lee, Jasmine Y, Stam, Ronald W, Goldsmith, Kelly C., Afd Pharmaceutics, Bate-Eya, Laurel T, Goldsmith, Kelly C   +28 more
core   +1 more source

Coexistence of immunophenotypically normal and aberrant mast cells in patients with clonal mast cell diseases associates with more indolent subtypes and less severe disease characteristics

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Aberrant antigen expression on mast cells (MCs) is one of the most accurate diagnostic markers for clonal MC diseases (CMCD). Although the coexistence of normal and pathologic MCs is frequently seen, the disease characteristics associated with it have been minimally investigated.
Abdulrazzaq Alheraky, Kees Meijer, Marije Nijk, Saskia K. Klein, Hanneke N. G. Oude Elberink, Ido P. Kema, André B. Mulder   +6 more
wiley   +1 more source

Venetoclax as a trigger for autoimmune hemolytic anemia in secondary acute myeloid leukemia: A case report

SAGE Open Medical Case Reports
Venetoclax, a BCL-2 inhibitor used in chronic lymphocytic leukemia and acute myeloid leukemia, has been rarely associated with autoimmune hemolytic anemia, mostly in chronic lymphocytic leukemia.
Karima Benallaoua, Pierre Lacoeuilhe, Benoît Gendrot, Sahra Muhammad, Guillemette Fouquet   +4 more
doaj   +1 more source

DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition

Biomolecules, 2020
Anti-apoptotic Bcl-2-family members are frequently dysregulated in both blood and solid cancers, contributing to their survival despite ongoing oncogenic stress.
Martijn Kerkhofs, Tamara Vervloessem, Kinga B. Stopa, Victoria M. Smith, Meike Vogler, Geert Bultynck   +5 more
doaj   +1 more source

Human biomarker navigator

iMeta, EarlyView.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li, Qian Zhang, Zijie Wang, Zeping Gui, Jing Liu, Jingda Li, Maojun Jiang, Zukang Chang, Qingqing Han, Bendong Yang, Tariq Saeed, Jun Li, Jinghan Jia, Chenghu Song, Tong Shao, Tianhuan Peng, Xueying Zhang, Pingping Guo, Jun Luo, Gangao Yang, Yuan Wan, Gokhan Zengin, Quan Yuan, Lingru Li, Xiaohui Fan, Yang Luo, Lvyun Zhu, Yanfei Zheng, Wenjun Mao, Wenlong Sun   +29 more
wiley   +1 more source

Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas

, 2017
Constitutive B-cell receptor signaling leads to overexpression of the antiapoptotic BCL-2 protein and is implicated in the pathogenesis of many types of B-cell non-Hodgkin lymphoma (B-NHL).
Brian G. Till, Oliver W. Press, Yukang Lin, Donald K. Hamlin, Damian J. Green, Aimee L. Kenoyer, Shyril O'Steen, Darrell R. Fisher, Theodore A. Gooley, Ajay K. Gopal, Amelia Waltman, D. Scott Wilbur, Mark D. Hylarides, Johnnie J. Orozco   +13 more
core   +2 more sources

Pharmacological boosting of azacitidine/venetoclax in acute myeloid leukemia

Blood Neoplasia
: Azacitidine/venetoclax is the standard treatment for patients with acute myeloid leukemia (AML) unfit for intensive chemotherapy. Cytochrome P450 3A4 (CYP3A4) is the major metabolizing enzyme for venetoclax, and its inhibition can boost venetoclax.
Niels Westra, Elena Ropero Cerro, Edwin Schilder, Marjolijn N. Lub-de Hooge, Daan J. Touw, Jos G. W. Kosterink, Dana A. Chitu, Emanuele Ammatuna, Saskia K. Klein, Peter E. Westerweel, Marloes Cuijpers, Marjan Cruijsen, Maarten M. F. Corsten, Canan Alhan, Lidwine Tick, Jan Jacob Schuringa, Gerwin Huls, Carolien M. Woolthuis, Thijs H. Oude Munnink   +18 more
doaj   +1 more source

Hsp90 Inhibition on the Western Blot: N‐Terminal Versus C‐Terminal Inhibitors in Breast Cancer

Medicinal Research Reviews, EarlyView.
ABSTRACT Heat shock protein 90 (Hsp90) is an established and clinically validated anticancer target. By regulating the folding and maturation of diverse client proteins, it is indirectly involved in carcinogenesis. Key breast cancer oncogenic drivers, including estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, are ...
Jaka Dernovšek, Jernej Cingl, Urša Pečar Fonović, Tihomir Tomašič   +3 more
wiley   +1 more source